On November 1, 2019 Nektar Therapeutics (NASDAQ:NKTR) reported that it will webcast an analyst and investor conference call with a melanoma specialist and company management on Sunday, November 10, 2019 at 9:00 a.m. EST in Washington, D.C. during the 2019 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting (Press release, Nektar Therapeutics, NOV 1, 2019, https://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-with-melanoma-specialist-for-analysts–investors-during-2019-society-for-immunotherapy-of-cancer-34th-annual-meeting-300949732.html [SID1234550190]). The call will be hosted by Nektar management and will also include Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center. The event will follow Dr. Diab’s oral presentation on Saturday evening of clinical data from a cohort of first-line Stage IV metastatic melanoma patients in the PIVOT-02 study of NKTR-214 in combination with nivolumab.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Analyst Call with Melanoma Specialist
Date: Sunday, November 10th at 9:00 a.m. Eastern Standard Time
Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 9059428)
Investors and analysts can also view slides and listen to the live audio webcast of the presentation at View Source The event will also be available for replay for two weeks on the company’s website, www.nektar.com.
Details of the oral presentation at SITC (Free SITC Whitepaper) are as follows:
Oral Presentation at SITC (Free SITC Whitepaper)
Date: Saturday, November 9th from 5:15 p.m. – 5:30 p.m. Eastern Standard Time
Session Title: Concurrent Session 310: Combination Phase 1-2 Clinical Trials
Abstract Title: "Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study"
Abstract: O35
Presenter: Dr. Adi Diab, MD Anderson Cancer Center
Details of the poster presentations are as follows:
Additional Presentations at SITC (Free SITC Whitepaper)
Abstract P619: "NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models", Kivimäe, S., et al.
Session Date and Time: Friday, November 8th from 7:00 a.m. – 8:00 p.m. Eastern Standard Time
Abstract P623: "Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity", Pieper, A., et al.
Session Date and Time: Friday, November 8th from 7:00 a.m. – 8:00 p.m. Eastern Standard Time
Abstract P622: "Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist", Miyazaki, T., et al.
Session Date and Time: Saturday, November 9th from 7:00 a.m. – 8:00 p.m. Eastern Standard Time
Details of the Trials in Progress poster presentation are as follows:
Trials in Progress Poster Presentation at SITC (Free SITC Whitepaper)
Abstract P387: "A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer (PORTER)", Nissola, L., et al.
Session Date and Time: Friday, November 8th from 7:00 a.m. – 8:00 p.m. Eastern Standard Time